ALNY Stock Overview
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Alnylam Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$225.40 |
| 52 Week High | US$242.97 |
| 52 Week Low | US$117.58 |
| Beta | 0.50 |
| 1 Month Change | -5.15% |
| 3 Month Change | 5.16% |
| 1 Year Change | 55.52% |
| 3 Year Change | 87.90% |
| 5 Year Change | 84.50% |
| Change since IPO | 3,650.42% |
Recent News & Updates
Recent updates
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?
Oct 25
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Using Debt In A Risky Way?
Jun 21Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Using Debt In A Risky Way?
Oct 25Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 49%?
Sep 20Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Using Debt In A Risky Way?
Jul 03Are Investors Undervaluing Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) By 48%?
Jun 07We Discuss Why Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) CEO May Deserve A Higher Pay Packet
May 12Shareholder Returns
| ALNY | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.2% | -1.4% | 0.2% |
| 1Y | 55.5% | 1.2% | -13.6% |
Return vs Industry: ALNY exceeded the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: ALNY exceeded the US Market which returned -9.2% over the past year.
Price Volatility
| ALNY volatility | |
|---|---|
| ALNY Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 12.3% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ALNY is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: ALNY's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 1,665 | Yvonne Greenstreet | https://www.alnylam.com |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company’s pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1).
Alnylam Pharmaceuticals, Inc. Fundamentals Summary
| ALNY fundamental statistics | |
|---|---|
| Market Cap | US$27.73b |
| Earnings (TTM) | -US$1.18b |
| Revenue (TTM) | US$960.92m |
28.9x
P/S Ratio-23.5x
P/E RatioIs ALNY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALNY income statement (TTM) | |
|---|---|
| Revenue | US$960.92m |
| Cost of Revenue | US$155.22m |
| Gross Profit | US$805.70m |
| Other Expenses | US$1.99b |
| Earnings | -US$1.18b |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.61 |
| Gross Margin | 83.85% |
| Net Profit Margin | -123.02% |
| Debt/Equity Ratio | -1,502.1% |
How did ALNY perform over the long term?
See historical performance and comparison